News | November 20, 2023
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Subscribe To Our Newsletter & Stay Updated
